CAR T-cell Therapy Success Rate in Israel
CAR T-cell Therapy Success Rate at Sheba Medical Center Stands at 70%
The advanced therapy, available only in select medical institutions around the world, is a highly effective treatment for patients with relapsed or refractory cancer
CAR T-cell therapy is an innovative procedure that makes use of your own immune system to seek and destroy cancerous cells. After some blood is taken from the patient, the T-cells, a type of immune cell, are separated from the rest of the blood in a special laboratory. The T-cells are then genetically engineered to produce chimeric antigen receptors (CARs). The engineered T-cells are then given some time to multiply in the laboratory and are later injected back into the patient. The CARs allow the T-cells to recognize, target and destroy the cancer cells. The whole process takes approximately 10 days, but patients are hospitalized for a minimum of 2 weeks to monitor toxicities. A cutting-edge treatment, the success rate of CAR T-cell therapy is very high compared to standard treatments, such as radiation and chemotherapy, especially in relapsed or refractory patients.
What Are The Success Rates?
Research on the use of immune system T-cells for cancer treatment started 25 years ago in Israel, and during the past five years, clinical trials conducted in Israel and around the world have demonstrated the great efficacy of this therapy. According to recent studies, the success rates of CAR T-cell therapy globally stand at 50-80% on average. At Sheba Medical Center in Israel, the first institution to offer CAR T-cell therapy outside the US, the success rates are 85-90% in young children, about 80% in teenagers, and approximately 70% in the general population.
The Benefits of Choosing Israel for CAR T-cell Therapy
Medical institutions in Israel and the US often collaborate in advanced cancer research, developing new and effective treatments against the disease, yet Israel has fewer constraints than the US when it comes to adopting novel treatments. Israeli clinical trials still adhere to the highest standards of safety, but innovative treatments are generally made available to patients sooner than in the US.
Quality of Care:
Israeli physicians are exceptionally well-trained and often spend even more time on their medical education than American doctors. Also, you can be assured of high standards and strict safety regulations if you choose a hospital accredited by a trustworthy authority.
In many countries, healthcare costs can be exorbitant. Without insurance, the price of cancer treatment can be crippling. Costs are much lower in Israel, averaging 30-80% less than in the US, for example.
Where to Pursue CAR T-cell Therapy in Israel
As a government institution, we have no hidden costs, and our fees are transparent.
World-renowned specialists: Our staff includes some of the most qualified and experienced oncologists, hematologists, and immunologists in the world.
The 360-degree care approach to healthcare at Sheba means that our team will help you arrange medical record reviews, travel visas, accommodations, and language interpretation, while at the same time helping you maintain your quality of life and overall well-being throughout your treatment.
We are fully accredited for international healthcare by the Joint Commission International (JCI), the premier international healthcare accrediting group.
Convenient on-site care: We offer all of the required services for CAR T-cell therapy under-one-roof, including blood collection, chemotherapy, a genetic engineering laboratory, T-cell injections, and patient monitoring, resulting in an efficient and expedited treatment.
Sheba is home to the Ella Lemelbaum Institute for Immuno-Oncology, a modern facility devoted entirely to cancer immunotherapy research and treatment.
Sam Turel’s Story – CAR T Treatment at Sheba Medical Center
According to Sam:
“I was aware of treatment options such as CAR T-cell therapy, and my neurosurgeon brother suggested getting treatment at Sheba Medical Center in Israel. We had explored other international hospitals, such as MD Anderson in Houston, TX, but they only had a program to treat DLBCL with this therapy, or a 2-year clinical trial to treat both DLBCL and CLL. The latter was an experimental program spread out over a long period that required temporary relocation to the United States. Sheba Medical Center had a program to treat both DLBCL and CLL with CAR T treatment. Because of their on-site lab, the entire treatment would take 8-10 weeks, maximum. Additionally, the cost of the treatment in Israel was much more affordable than in the US.”
After receiving CAR T-cell therapy at Sheba, Sam’s CLL went into full remission.
Request a consultation
Sheba Medical Center provides innovative, personalized medical care to patients from around the world. We are the largest, most comprehensive hospital in the Middle East and dedicated to providing advanced and compassionate medicine for everyone.
We welcome all cases, including the rarest and the most challenging. Our medical teams collaborate to provide the best possible health outcomes. From your initial inquiry through the long-term follow-up care, we are here for you.
Request a consultation and a Sheba Case Manager will contact you shortly: